Related Experiment Video

Updated: Jan 23, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.0K

Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer

Nan Shao1, Yawei Shi1, Liang Yu1

  • 1Breast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, ZhongShan Er Lu, Guangzhou, Guangdong, 510080, P.R. China.

International Journal of Biological Sciences
|June 12, 2019
PubMed

Insights

Targeted therapies, including poly (ADP-ribose) polymerase inhibitors (PARPi), show promise for HER2-negative metastatic breast cancer (BC). Research focuses on BRCA1/2 mutations, BRCAness, and combinations with chemotherapy for improved patient outcomes.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Human epidermal growth factor receptor (HER2) negative metastatic breast cancer (BC) represents a significant majority (73%) of all breast cancer cases.
  • Molecular profiling is crucial for identifying targeted therapy options for this patient population.
  • Emerging strategies include endocrine therapy, chemotherapy, angiogenesis inhibitors, immune checkpoint inhibitors, and anti-androgens.

Purpose of the Study:

  • To review recent advancements in targeted therapies for HER2-negative metastatic breast cancer.
  • To summarize outcomes from recent clinical trials.
  • To provide an overview of ongoing clinical trials for patients with BRCA1/2 mutations and BRCAness.

Main Methods:

  • Literature review of recent developments in targeted therapy for HER2-negative breast cancer.
  • Analysis of clinical trial outcomes and ongoing studies.
  • Focus on poly (ADP-ribose) polymerase inhibitors (PARPi) and their role in BRCA-mutated and BRCAness tumors.

Main Results:

  • Poly (ADP-ribose) polymerase inhibitors (PARPi) demonstrate efficacy in both germline and somatic BRCA1/2 mutations.
  • PARPi function as chemo- and radio-sensitizers by impairing DNA damage response.
  • Combinations of PARPi with chemotherapy and targeted agents are under investigation for HER2-negative BC.

Conclusions:

  • Targeted therapies, particularly PARPi, offer new avenues for HER2-negative metastatic breast cancer treatment.
  • Understanding germline and somatic mutations, including BRCAness, is key to optimizing PARPi therapy.
  • Ongoing clinical trials are exploring novel combinations to improve treatment efficacy in this disease subset.
Keywords:
BRCABRCAnessHer2 negative breast cancerPARP inhibitorstargeted therapy

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

854

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.3K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Positive, Negative, and Zero Work00:58

Positive, Negative, and Zero Work

Work is done on an object when energy is transferred to the object. In other words, work is done when a force acts on a body that undergoes a displacement from one position to another. By definition, the work done by a force is the integral of the force with respect to the displacement along its path. Forces can vary as a function of position, and displacements can occur along various paths between two points. The magnitude of a force multiplied by the cosine of the angle that the force makes...
22.1K
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
501
Positive and Negative Feedback Loops01:18

Positive and Negative Feedback Loops

Animal organs and organ systems constantly adjust to internal and external changes through a process called homeostasis ("steady state"). Examples of these changes include regulation of the level of glucose or calcium in the blood or internal responses to external temperatures. Homeostasis requires  maintaining an internal dynamic equilibrium:
25.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
616